Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

Recruiting now · Not applicable

Conditions studied: Non-metastasized Unresectable Pancreatic Carcinoma

In brief

This is a multicenter randomized phase II trial that aims to include 160 patients with a non-metastatic (localized), inoperable pancreatic tumor. The study will take place at multiple centers across Europe. The primary objective of the study is to demonstrate superiority in progression free survival (PFS) by adding stereotactic body radiation therapy (SBRT) to chemotherapy for patients with an inoperable non-metastasized pancreatic tumor. SBRT is a radiotherapy technique (i.e. destroying cancer cells by means of ionizing irradiation) in which tumors can be irradiated with a high radiation dose. Surrounding healthy tissue is thus spared to the maximum extent. The primary endpoint of the TORPEDO study is 2-year PFS defined as the percentage of patients who are free of disease progression at 110 weeks after the date when the patients were drawn into 2 treatment groups (i.e. randomization). Secondary outcomes are, among others, quality of life, acute and late toxicity (i.e. adverse events), metastasis-free survival, local progression-free survival, overall survival, subsequent resectability, R0 resection and surgical morbidity. During the study, patients without disease progression after 3 months of induction chemotherapy will be randomized 1:1 to either treatment with chemotherapy or treatment with a combination of chemotherapy and SBRT (5 x 8 Gy). After randomization, ten-weekly follow-up visits will occur during two years to evaluate the quality of life, general blood parameters and general health condition of the patient. Moreover, toxicity will be evaluated as well as efficiency and safety of the treatment (e.g. by means of imaging). At any time during this follow-up period, imaging (CT scan, MRI scan) will be used to determine whether surgery can still be performed to improve patient survival.

Key facts

Study ID: NCT06691425
Run by: Cancer Research Antwerp
People needed: 160
Starts: 2024-07-19
Expected to finish: 2030-07-01
Last updated by the study team: 2025-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participant must be over 18 years of age.
Participant is able and willing to provide written informed consent which includes compliance with and ability to undergo all study procedures and attend the scheduled follow-up visits per protocol.
Either locally advanced or borderline resectable pancreatic adenocarcinoma, as confirmed by diagnostic images (CT, MRI or PET-CT scan) and based on vessel involvement according to the NCCN guidelines. Only borderline resectable pancreatic cancer (BRPC) patients who are medically unfit for surgery or refusing surgery can be included.
Adequate organ function determined by the following laboratory values:
Adequate bone marrow function: absolute neutrophil count ≥1500/mm\^3, platelet count ≥100000/mm\^3 and hemoglobin ≥9 g/dl
Adequate renal function: Creatinine ≤1.5 x upper normal limit of normal (ULN) or estimated eGFR more than 45 ml/min
Adequate liver function: total bilirubin ≤1.5 ULN (after adequate biliairy stenting with metal stent) and alanine aminotransferase (ALT) ≤5x ULN
An Eastern Cooperative Oncology Group (ECOG) performance status grade of 0-2.
A life expectancy ≥3 months
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
Is not a woman of child bearing potential or
A woman of child bearing potential must have a negative serum pregnancy test at screening and must use a very effective method of birth control.

You may not qualify if…

Extrapancreatic metastatic disease as defined on diagnostic imaging (CT, MRI or PET-CT scan) or laparoscopy, including distal nodal involvement beyond the peripancreatic tissues and/or distant metastases.
Massive gastric or intestinal invasion as assessed on imaging and/or endoscopy. Direct invasion of the duodenal mucosa as visible on endoscopic ultrasound (EUS).
Prior radiation therapy that could hamper adequate dose delivery
Contraindication to magnetic resonance imaging (MRI)
Diagnosis of another malignancy within 2 years prior to randomization, except non-melanoma skin cancer, non-invasive bladder cancer, carcinoma in situ of the cervix or non-metastatic prostate cancer. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment.
Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject.
Patient already included in another clinical trial that would interfere with the TORPEDO clinical trial, as assessed by the Investigator.
Known presence of an active ulcer (i.e. detected during standard of care diagnostic assessments)
Additional exclusion criteria after restaging (i.e. within 1 week after 3 months of induction chemotherapy) and prior to randomization:
Extrapancreatic metastatic disease as defined on diagnostic imaging, including distal nodal involvement beyond the peripancreatic tissues and/or distant metastases
Massive gastric or intestinal invasion as assessed on imaging and/or endoscopy. Direct invasion of the duodenal mucosa as visible on EUS.
Known presence of an active ulcer (i.e. detected during standard of care diagnostic assessments)

Where it is running

UZA — Edegem, Antwerpen, Belgium (enrolling)
ZAS Augustinus — Wilrijk, Antwerp, Belgium (enrolling)
AZ Klina — Brasschaat, Belgium (enrolling)
AZ Sint-Jan — Bruges, Belgium (enrolling)
ZOL — Genk, Belgium (enrolling)
Jessa ziekenhuis — Hasselt, Belgium (enrolling)
AZ Groeninge — Kortrijk, Belgium (enrolling)
AZ Delta — Roeselare, Belgium (enrolling)
AZ Turnhout — Turnhout, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.